SCHEMBL1764818

SCHEMBL1764818

CCC(CC)CNCCCCO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
TSHR P16473 3/20 0.41
CYP3A4 P08684 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.36
PKM P14618 1/20 0.35
ANPEP P15144 1/20 0.35
ERAP2 Q6P179 1/20 0.35
LMNA P02545 3/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
MAPK1 P28482 1/20 0.32
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CA12 O43570 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4394406 0.85 ALDH1A1 (0.62) ALDH1A1TSHRCYP3A4SMN1; SMN2ANPEP
SCHEMBL10045177 0.83 CYP2C19 (0.50) ALDH1A1TSHRCYP3A4PKMANPEP
SCHEMBL1761193 0.83 ALDH1A1 (0.41) ALDH1A1TSHRCYP3A4SMN1; SMN2ANPEP
SCHEMBL10045169 0.83 CYP2C19 (0.50) ALDH1A1TSHRCYP3A4PKMANPEP
SCHEMBL10045097 0.80 ALDH1A1 (0.48) ALDH1A1TSHRCYP3A4PKMANPEP
SCHEMBL29001373 0.79 ALDH1A1 (0.67) ALDH1A1TSHRCYP3A4SMN1; SMN2ANPEP
SCHEMBL11663277 0.79 TSHR (0.55) ALDH1A1TSHRCYP3A4ANPEPERAP2
SCHEMBL8528177 0.78 ALDH1A1 (0.58) ALDH1A1TSHRCYP3A4SMN1; SMN2ANPEP
SCHEMBL10045184 0.77 CYP2C19 (0.64) ALDH1A1TSHRCYP3A4PKMANPEP
SCHEMBL21799824 0.77 CA12 (0.50) ALDH1A1TSHRCYP3A4SMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518966-B2 Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists THERAVANCE, INC. (US) 2013-08-27 US disclosed
EP-2185553-B1 AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS THERAVANCE INC (US) 2012-06-27 EP disclosed
US-20110124677-A1 AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS THERAVANCE, INC. (US) 2011-05-26 US disclosed
US-7902221-B2 Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists THERAVANCE, INC. (US) 2011-03-08 US disclosed
EP-2185553-A1 AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS Theravance, Inc. (US) 2010-05-19 EP disclosed
US-20090062335-A1 Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists THERAVANCE, INC. 2009-03-05 US disclosed
WO-2009029252-A1 AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS THERAVANCE, INC. (US) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124677-A1 AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS OPRM1, OPRL1, OPRK1 ALDH1A1 1204/4885TSHR 228/4885CYP3A4 733/4885
US-20090062335-A1 Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists OPRM1, OPRL1, OPRK1 ALDH1A1 1011/4885TSHR 205/4885CYP3A4 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.